Inhaled corticosteroids (ICSs) are indicated for the prevention of exacerbations in COPD;
however, a significant proportion of patients at low risk of exacerbations are treated with …

Background The use of inhaled corticosteroids (ICSs) is associated with an increased risk of
pneumonia in patients with COPD. However, the risks of other respiratory infections, such as …

Background Inhaled corticosteroids (ICS) have been shown to decrease the occurrence of
COPD exacerbations. However, the relationship of baseline lung function and reduction of …

Background The use of inhaled corticosteroids (ICS) in combination with bronchodilators in
patients with COPD has been shown to decrease the rate of disease exacerbations and to …

Background: Inhaled corticosteroids are commonly prescribed for patients with severe
COPD. They have been associated with increased risk of pneumonia but not with increased …

Inhaled corticosteroids (ICS) reduce COPD exacerbation frequency and slow decline in
health related quality of life but have little effect on lung function, do not reduce mortality, and …

Background The widespread use of inhaled corticosteroids (ICSs) for COPD treatment has
been questioned. Recent studies of weaning some patients with COPD off ICSs found little …

Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …

Inhaled corticosteroids (ICS) are important in reducing exacerbation frequency associated
with chronic obstructive pulmonary disease (COPD). However, little is known about the risk …

Objective Inhaled corticosteroids (ICS) are generally used to treat patients with chronic
obstructive pulmonary disease (COPD) who suffer from repeated exacerbations. Recently, it …